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I. INTRODUCTION

Mining large data sets for hidden connections promises to
improve almost every sector of society, from business to government,
academia, and private life. But some of the more compelling uses of
"big data" are in health care. Predictive analytics might help us
diagnose diseases more quickly, treat medical conditions more
effectively, deploy scarce health resources more efficiently, and even
improve the way we maintain our minds and bodies. Already, big data
is being marshaled to these ends by nearly every major constituent of
our health care system, including hospitals, insurers, practitioners,
* Callejo Endowed Professor, Associate Dean for Research, and Gerald J. Ford Research
Fellow, SMU Dedman School of Law. I thank participants at events at Ohio State and
Stanford for their comments and questions on earlier drafts, particularly Efthimios
Parasidis and Jessica Roberts.

62

I/S: A JOURNAL OF LAW AND POLICY

[Vol- 14.1

patients, researchers, product manufacturers, and government
programs.
As data collection becomes more pervasive (and invasive), and as
machine learning and analytical methods become more sophisticated,
big data's predictive power will intensify. And as the big data industry
matures, the companies that traffic in health-related big data will face
competitive pressures to make more aggressive claims regarding what
their analytics can predict. One can imagine, for example, hospital
systems making speculative claims to treat cancers more effectively
than competitors based on their use of proprietary data analytics, or
insurers marketing data-driven plans that promise massive costsavings. Already, patients and practitioners are inundated with claims
by thousands of smartphone apps that promise to use data in novel
ways to diagnose or manage scores of medical conditions. In short,
our health system may become flooded with claims that big data and
predictive analytics can solve our most pressing problems.
This article considers the level of evidence and substantiation that
we should require of big data claims-focusing on "health claims," or
claims to diagnose, treat, or manage diseases or other medical
conditions. Currently, there are three very different paradigms that
might apply to such claims, depending on whether the predictions are
cast as medical products, as medical practice, or merely as medical
information. For example, should we treat predictive analytics akin to
products like radiation treatment planning software, subject to
controls on how it is manufactured and marketed? Or, is predictive
analytics more akin to professional medical practice, and amenable to
soft oversight by state licensors, practice guidelines, and medical
specialty societies? Or is it most like medical information
disseminated through journals, books, and the like, subject only to
peer review?
I argue that because big data in health care is so opaque-both the
data and the processing--big data claims may be uniquely difficult to
substantiate, and thus call for a new paradigm. To date, scholars have
considered new paradigms for big data privacy, research ethics, and
the like. But this article considers what the contours of a new
paradigm for evaluating big data health claims might look like,
articulating key principles based on how predictive analytics departs
from more traditional medicine.
II. BIG DATA'S BREADTH

Among the many challenges in substantiating big data health
claims, three stand out. First is the volume and variety of data sources.

2017]

CORTEZ

63

Second is the breadth, complexity, and fluidity of the methods for
processing the data. Third is the breadth of different uses, some of
which may require very different levels of substantiation.
A. Breadth ofSources
Almost everyone and everything that touches the U.S. health
system contributes data to it. Big data in health care derives from
patients, practitioners, hospitals, researchers, pharmacies, insurers,
manufacturers, regulators, and countless other sources. Some sources
are familiar, such as electronic medical records (EMRs), electronic
health records (EHRs),' and insurance claims, including massive allpayer claims databases that collect medical, pharmacy, and dental
claims from both public and private payers.2 But big data also draws
from records of prescriptions, diagnostic imaging results, laboratory.tests (including genetic and genomic testing), outcomes reporting, and
the many other records generated during health care delivery and
payment. More recently, we have also begun to collect more
continuous and granular data from mobile devices such as
smartphones, wearables, ingestibles, implantables, and other
sensors. 3
These data sources are the product of perhaps hundreds of public
and private sector initiatives that have pushed for greater.
transparency, accountability, and efficiency in health care. Some wellknown programs have required great effort and expenses. For
example, in 2008 the FDA launched its Sentinel Initiative, a national
electronic system for monitoring safety problems with drugs, vaccines,

I

EHRs are much broader than EMRs, which are merely "a digital version of the paper
charts in the clinician's office," containing the patient's medical and treatment history at
that site. In contrast, the EHR is intended to span multiple providers and facilities,
traveling with the patient. See Peter Garrett & Joshua Seidman, EMR vs. EHR - What is
the Difference?, HEALTH IT Buzz (Jan. 4, 2011), https://www.healthit.gov/buzz-

blog/electronic-health-and-medical-records/emr-vs-ehr-difference/
[https://perma.cc/UC79-Y9431.
Note, however, that in Gobeille v. Liberty Mutual Ins. Co., 136 S.Ct. 936, 954 (2016), the
Supreme Court invalidated a Vermont law that required reporting for its all-payer claims
database as preempted by ERISA, the Employee Retirement Income Security Act of 1974.
2

3 See, e.g., WILLIAM HANSON, SMART MEDICINE: HoW THE CHANGING ROLE OF DOCTORS
WILL REVOLUTIONIZE HEALTH CARE 153-54 (2011); ERIC TOPOL, THE CREATIVE
DESTRUCTION OF MEDICINE: How THE DIGITAL REVOLUTION WILL CREATE BETTER HEALTH

CARE 194-95 (2012); Nathan Cortez, The Mobile Health Revolution, 47 U.C. DAVIS L. REV.
1173, 1197-98 (2014) [hereinafter Cortez, Mobile Health Revolution].
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biologics, and medical devices, relying on data from EHRs, insurance
claims, and other heterogeneous sources. 4 Since 2011, the federal
government has given billions of dollars to Medicare and Medicaid
providers that can demonstrate their "meaningful use" of EHRs in
practice;, with the idea that such use will improve clinical outcomes,
reduce inefficiencies, and better engage patients in their own care.5 In
2013, the Wall Street Journal and the Center for Public Integrity
convinced a court to overturn a 33 year-old injunction that prevented
the Centers for Medicare and Medicaid (CMS) from releasing any
federal payment data that identified individual providers, thus
releasing Medicare payment data for roughly 825,000 practitioners.6
And today, the CMS websites HospitalCompare, Physician Compare,
and Nursing Home Compare provide quality data on thousands of
Medicare providers.7
These represent just a few of the high-profile efforts to gather and
disseminate data in the health sector. The volume and variety of data
sources continues to grow almost exponentially. In 2012, worldwide
health data occupied around 5oo petabytes of memory (about lo

4 U.S. FOOD & DRUG ADMIN. (FDA), FDA's SENTINEL INITIATIVE,

https://www.fda.gov/Safety/FDAsSentinellnitiative/default.htm [https://perma.cc/SY6RMHCQ]. The Sentinel Initiative was created by the Food and Drug Administration
Amendments Act of 2007 (FDAAA), Pub. L. No. 110-85, § 905, 121 Stat. 823, 944 (2007).
s U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS), DATA AND PROGRAM
REPORTS, CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS),

https://www.cms.gov/regulations-andguidance/legislation/ehrincentiveprograms/dataandreports.html
[https://perma.cc/4PZG-X7GC] (reporting more than $24 billion spent by the Medicare
EHR Incentive Program and $11.6 billion by the Medicaid EHR Incentive Program from
2011 through March 31, 2017). These payments derive from the Health Information
Technology for Economic and Clinical Health Act (HITECH Act), as part of the American
Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, tit. XIII, §§ 13001-13424, 123
Stat- 115, 226-79 (2009) (codified as amended in scattered sections of the U.S. Code).
For a history detailing the litigation, see Erik Wemple, Why Creditthe Wall Street
Journalon the Medicare DataRelease?, WASH. POST (Apr. 11, 2014),
https://www.washingtonpost.com/blogs/erik-wemple/wp/2014/04/11/why-credit-thewall-street-journal-on-the-medicare-data-release/ [https://perma.cc/QV5K-UG9J]. For
the court order freeing the data, see Order, Fla. Med. Ass'n v. Dep't of Health, Educ.,
Welfare, 947 F. Supp. 2d 1325 (M.D. Fla. 2013) (No. 3:78-cv-178-J-34MCR),
http://hr.cch.com/hld/FloridaMedicalAssociationvDeptofHealthEducationandWelfare.pdf
[https://perma.c/7A7J-YRQ4].
&

6

For an analysis of these data efforts, see Nathan Cortez, Regulation by Database,89
COLO. L. REV. (forthcoming 2017),
https://papers.ssrn.com/sol3/papers.cfn?abstract-id=2951968.
7

CORTEZ

2017]

65

billion four-drawer filing cabinets). 8 But by 2020, health data will
occupy roughly 50 times more, growing to 25,000 petabytes (5oo
billion cabinets).9 Moreover, even data traditionally situated outside
the health sector--such as shopping patterns, GPS location data, web
surfing habits, social media use, and the like-can be used to make
important inferences about one's health. Now, even ostensibly nonhealth data can be "medically inflected."o As a result, any standards
for substantiating big data health claims must account for the sheer
volume and variety of data sources.
B. Breadth of Methods
The second complication for substantiating big data health claims
is understanding the analytical methods used-no small feat.
Predictive analytics, writ large, draws inferences from large data sets,
relying on hypothesis-free data mining and inductive reasoning to
uncover patterns." Ziad Obermeyer and Ezekiel Emanuel explain that
machine learning "approaches problems as a doctor progressing
through residency might: by learning rules from data," taking patientlevel data to "sift through vast numbers of variables, looking for
combinations that reliably predict outcomes."12 Nicholson Price
describes the process as a computer system "trying a certain solution,
evaluating the outcome, and then modifying that solution accordingly
8 Silvia Piai & Massimiliano Claps, Bigger Datafor BetterHealthcare, in IDC HEALTH
INSIGHTS 3 (Sept. 2013), http://www.intel.com/content/www/us/en/healthcareit/solutions/documents/bigger-data-better-healthcare-ide-insights-white-paper.html
[https://perma.ce/9GZ3-9B4S] (click "Download the full report").
9

Id.

1o Nicolas Terry, ProtectingPatientPrivacy in the Age ofBig Data, 81 U. MISSOURIKANSAS CITY L. REv. 1, 9 (2012). To truly appreciate the breadth of big data sources in

health care, see Isaac Kohane, Finding the Missing Link for Big BiomedicalData,
https://dbmi.hms.harvard.edu/sites/g/files/mcu491/f/JvPl4oo57f-1o5ox855.png
[https://perma.cc/4CPW-EJ9T].

11 For reasonably

accessible descriptions of the different methods and how they evolved,

see PEDRO DOMINGOS, THE MASTER ALGORITHM: HOW THE QUEST FOR THE ULTIMATE
LEARNING MACHINE WILL REMAKE OUR WORLD (2015); PETER FLACH, MACHINE LEARNING:
THE ART AND SCIENCE OF ALGORITHMS THAT MAKE SENSE OF DATA 361-62 (2012). For a

&

more concise description, see W. Nicholson Price II, Black Box Medicine, 28 HARv. J.L.
TECH- 419,432-34 (2014-15).
- Ziad Obermeyer & Ezekiel J. Emanuel, Predictingthe Future- Big Data, Machine
Learning, and ClinicalMedicine, 375 NEW ENG. J. MED. 1216, 1217 (Sept. 29, 2016).
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to improve future outcomes," using as examples Pandora (music) and
Netflix (movies).13 Of course, there are numerous variations of
predictive analytics, including natural language processing, signal
processing, topic modeling, pattern recognition, machine learning,
deep learning, neural networks, and other advanced statistical
methods.
If the breadth of methods is not daunting enough, consider that
the methods themselves can be exceedingly complex and opaque, even
to the programmers responsible for applying them.14 One, the
relationships identified often remain hidden, even if the machine
learning process is transparent and understood.15 Two, the methods
continuously evolve, are adapted to different circumstances, and can
be combined to amplify their predictive power, making each use a
moving target.16 Three, the methods and applications may be
proprietary and thus not available for scrutiny by third parties. Thus,
in many instances, no one really understands or can explain the
complex biological relationships identified by a predictive analytics
program.17
C. Breadth of Uses
The third challenge for substantiating big data claims is the
breadth of different uses. Big data is being marshaled for clinical
decision support and patient care, including diagnosis, treatment, and
chronic disease management. It is also a tool for hospitals and
insurers (the latter somewhat problematically) to optimize triage and
resource allocation decisions. Finally, big data is particularly
compelling in biomedical research, including drug discovery and the
development of novel diagnostic tools. Consider the following
examples.
Physicians are making use of clinical decision support (CDS)
systems that can turn vast amounts of data into actionable advice.' 8
13

Price, supra note 11, at 432.

14 Id. at 433.
s Id.
16 See DO1vHNGOS, supra note 11, for a history of this evolution.
17 Price, supra note 11, at 434.

18 See, e.g., John D. Halamka, EarlyExperiences with Big Dataat an Academic Medical
Center, 33 HEALTH AFF. 1132, 1133 (July 2014).
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Although the use of automated decision support is not at all new,1 9 the
sheer volume of data available today-as well as the shift from rulebased systems modeled on experts to rules-generating machine
learning2o-makes CDS systems much more powerful. A modern CDS
system may be fed by millions of pages of electronic health records,
laboratory results, vital sign readouts, prescription histories, radiology
images, as well as vast libraries of medical literature, including best
practice guidelines from expert societies. Without automation, the
volume of information can overwhelm. Indeed, it can take an hour for
a clinician to fully review just a single patient's EHR.21 But CDS
systems can process these data to identify meaningful trends and
events, and thus recommend in real-time a specific diagnostic test, a
change in medication, or an intervention that improves the patient's
outcome, conserves resources, or perhaps both.22 CDS thus allows
clinicians to review a menu of evidence-based suggestions rather than
the raw, underlying data.23
At the institutional level, hospitals and health systems can use
predictive analytics for triage, resource allocation, and quality
enhancement efforts. For example, a single hospital might use big
data to better manage high-cost patients, reduce hospital
readmissions, triage clinical workflows to the most pressing cases,
predict which patients' conditions might worsen and when
(decompensation), predict adverse events, and better manage costly
chronic conditions based on longitudinal data.24 One model is Kaiser
Permanente, which maintains 44 petabytes of EHR data for its
roughly nine million patients-44-times more data than that
contained in the entire Library of Congress.25
19 Nathan Cortez, Analog Agency in a Digital World, in FDA IN THE 21ST CENTURY: THE
CHALLENGES OF REGULATING DRUGS AND NEW TECHNOLOGIES 438, 439-40 (Holly

Fernandez Lynch & I. Glenn Cohen, eds., 2015) [hereinafter Cortez, Analog Agency].
20 Obermeyer & Emanuel, supranote 12.
21 Halamka, supranote 18, at 1133.
22

Id.

23

Id.

24

David W. Bates et al., Big Data in Health Care: Using Analytics to Identify andManage
1128 (2014).

High-Risk andHigh-Cost Patients,33 HEALTH AFF. 1123,
25

Caitlin M. Cusack et al., The FutureState of ClinicalDataCaptureand Documentation:

A Reportfrom AMIA's
(2013).

2011

PolicyMeeting, 20(1) J. AM. MED. INFORMATICS AsS'N 134
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Kaiser's integrated EHR system has saved it roughly $i billion by

reducing laboratory tests and physician office

visits.2

6

One ambitious

estimate predicts that the use of big data in health care could save
between $300-45o billion in annual spending.27 Moreover, new
government reimbursement models that encourage patient outcome
tracking and cost-conscious delivery, such as Accountable Care
Organizations (ACOs),2 8 may generate further data innovations.
Predictive analytics are also being incorporated into diagnostics.
For example, the company Foundation Medicine markets "nextgeneration sequencing" (NGS) assays that can sequence cancer cells
(located in solid tumors or circulating in the blood) and predict which
therapies might best target the cancer based on its specific mutations
and alterations.29 The assay tests the entire coding sequences of 315
genes (plus introns from 28 additional genes) known to be related to
cancer.

Another example is the Veterans Health Administration (VHA),
which services over eight million patients through roughly 150
medical centers and 1,400 clinics. The VHA has been eager to adopt
mobile health and big data tools to improve diagnosis and
treatment. 30 One such use is the Durkheim Project, a collaboration
between the VHA and Facebook, which tries to predict suicide risk by
gathering data from veterans that choose to share information from

26 Basel Kayyali, David Knott, & Steve Van Kuiken, The Big Data Revolution in U.S. Health

Care:Accelerating Value andInnovation, MCKINSEY & Co. (Apr. 2013),
http://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/thebig-data-revolution-in-us-health-care [https://perma.cc/V2GK-LM3Y].
27 PETER GROVES, BASEL KAYYALI, DAVID KNOTT & STEVE VAN KUIKEN, CTR. FOR U.S.

HEALTH SYS. REFORM, THE BIG DATA REVOLUTION IN HEALTH CARE: ACCELERATING VALUE
AND INNOVATION 8 (2013),

https://www.ghdonline.org/uploads/BigDataRevolution-inhealth-care_2013_McKin
seyReport.pdf [https://perma.ce/6P6N-X8KA].
Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148,
119, 395 (2010) (current version at 42 U.S.C. § 1395iJi (2010)).
28

§

3022, 124 Stat.

What Is FoundationOne?,FOUND. MED.,
https://www.foundationmedicine.com/genomic-testing/foundation-one
[https://perma.cC/S28D-BN391.
29

30

Christopher Wasden, The Departmentof Veterans Affairs #mHealth Case Study,

HIMSS (Aug. 1, 2014), http://www.himss.org/department-veterans-affairs-mhealth-casestudy [https://perma.cc/2C32-DHDF].
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their social media accounts and mobile devices, applying real-time
prediction software.31

Yet another high-profile example is the use of IBM Watson's
famous "cognitive computing system" in cancer care. In 2011, IBM
partnered with the health insurer WellPoint to develop "a Watsonbased diagnosis and treatment decision support system for
oncology."32 In 2012, IBM then partnered with Memorial Sloan
Kettering Cancer Center to process vast quantities of medical
literature to generate recommendations for physicians, in theory
replacing the traditional "tumor board."33 Then in 2013, IBM and the
MD Anderson Cancer Center announced that they would apply
Watson to MD Anderson's large patient and research databases.34 The
idea was to combine data from diverse sources-patients, treatment
records, research, and medical literature-and use Watson's artificial
intelligence engine to recommend specific treatment options or
clinical trials for individual patients.35 As originally envisioned, the
goal was to "transform how medicine will be practiced, by leveraging
artificial intelligence," thus elevating the standard of cancer care

Jeff Bertolucci, Big Data ProjectAnalyzes Veterans'SuicideRisk, INFO. WK. (July 9,
2013), http://www.informationweek.com/big-data/big-data-analytics/big-data-project31

analyzes-veterans-suicide-risk/d/d-id/1ixo668 [https://perma.cc/ZPH2-Z9UT]; Joachim
Roski et al., CreatingValue in Health Care Through Big Data:OpportunitiesandPolicy
Implications, 33 HEALTH AFF. 1115, 1116 (2014).
SpecialReview of the ProcurementProceduresRelated to the M.D. Anderson Cancer
CenterOncology ExpertAdvisor Project (2016-17), UNIV. OF TEX. SYs. AUDIT OFF., 2

32

(2016),

https://www.utsystem.edu/sites/default/files/documents/UT%20System%2oAdministrati
on%2oSpecial%2oReview%2oofo2OProcurement%2OProcedures%2oRelated%20to%20U
TMDACC%2oOncology%2oExpert%2oAdvisor%2oProject/ut-system-administrationspecial-review-procurement-procedures-related-utmdacc-oncology-expert-advis.pdf
[https://permacc/3P66-AMNK] [hereinafter Universityof Texas Audit].
33 Matthew Herper, MD Anderson Benches IBM Watson in Setbackfor Artificial

Intelligence in Medicine, FORBEs (Feb. 19, 2017),
http://www.forbes.com/sites/matthewherper/2017/O2/19/md-anderson-benches-ibm-

watson-in-setback-for-artificial-intelligence-in-medicine/#67aal3137761
[https://perma.cc/J7FV-5SZ7]. Note, however, the emergence of "genomic tumor boards"
in which traditional tumor boards incorporate genomic data, including recommendations

from FoundationOne, into their discussions. See, e.g., Michelle L. McGowan et al., A Rising
Tide Lifts All Boats: Establishinga MultidisciplinaryGenomic Tumor Boardfor Breast
CancerPatientswith Advanced Disease, 9 BMC MED. GENOMICS no. 71, 2016, at 4.
34 Press Release, IBM, MD Anderson Taps IMB Watson to Power "Moon Shots" Mission
Aimed at Ending Cancer, Starting with Leukemia (Oct. 18, 2013).
35 University of Texas Audit, supranote 32, at 1.
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worldwide.3 6 The pilot first targeted leukemias, then expanded to lung
cancer.37
Other novel applications have also garnered widespread attention.
Google Flu Trends was an effort to combine flu-related search engine
queries with location data to predict in real time how cases of
influenza might be spreading.3 8 A later study showed that Google's
model predicted twice as many cases of the flu than the model used by
the Centers for Disease Control and Prevention (CDC).39 But even
after decommissioning Flu Trends in the United States, Google
continues to monitor flu activity in 25 other countries, noting that
"historically, national and regional estimates have been very
consistent with traditional surveillance data collected by health
agencies ... however, it is possible that future estimates may deviate
from actual flu activity."40 A similar location-based tool is Propeller
Health (formerly Asthmapolis), a GPS asthma tracker that records
symptoms and inhaler usage. 41 The program merges its data with data
from the CDC on pollen counts and other asthma triggers to develop
personalized recommendations for users.
Finally, one of the more compelling uses of big data and predictive
analytics in health care is for biomedical research, where researchers
are querying massive heterogeneous data sets to mine for hidden
relationships. Such queries have been facilitated by a few initiatives,
including Informatics for Integrating Biology & the Bedside (12B2), an
36 Id. at 2.

Id. at 3. The IBM-MD Anderson partnership met a disappointing end in 2017. When the
project was audited in 2016, it had not yet been approved for human investigational or
clinical use. In February 2017, MD Anderson announced that it was placing the project on
hold, opening the program to other bidders, after an audit by the University of Texas
System revealed that MD Anderson had paid over $62 million on the project (not including
internal resources) without much to show for it. See supra note 32. MD Anderson has
engaged separate consultants to evaluate the scientific bases and functional capabilities of
the system, but IBM defended Watson by noting that OEA's recommendations were go%
accurate when benchmarked with experts. See Herper, supra note 33.
37

38 Jeremy

Ginsberg et al., DetectingInfluenza Epidemics Using Search Engine Query

Data, 457 NATURE 1012, 1012 (2009).
39

Declan Butler, When Google Got Flu Wrong, 494 NATURE 155, 155 (2013).

40

Dawn Fallik, ForBig Data, Big Questions Remain, 33 HEALTH AFF. 1111, 1112 n.6

(quoting Google Flu Trends, Frequently Asked Questions, at
http://www.google.org/flutrends/about/faq.htnil (last accessed May 30, 2014)).
41

Tim Maly, Asthmapping: Smart InhalersTrack Usage to Save Lives, WIRED (Nov. 1,
https://www.wired.com/2012/11/asthmapolis/ [https://perma.cc/5PF8-2JP4].

2012),
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open-source software tool developed at Harvard to help researchers
mine clinical data,42 and Query Health, a broad methodology for
querying hospital big data developed by the Office of National
Coordinator for Health IT (ONC) within the U.S. Department of
Health and Human Services (HHS).43
III. CONCERNS, OLD AND NEW

The use of big data and predictive analytics in health care raises a
number of novel legal and ethical concerns. For example, can insurers
use predictive analytics to offer customized plans without violating
laws that ban health status underwriting?44 Does big data offer a
stealth way for insurers to identify preexisting conditions and other
health status factors?45 Do patients have to give informed consent,
before their personal data are used in predictive models, or when they
are subject to treatment decisions based on automated support?4 6 Will
hospitals or practitioners face liability for relying on a predictive
model that errs, or for not following a valid recommendation?47 What
dangers lurk when big data practices fall outside the scope of health
privacy laws like HIPAA? How can we detect and prevent errors
caused by complex, opaque computer code? How does humancomputer interaction skew clinical decision-making and judgment?
4Introduction,12B2: INFORMATICS FOR INTEGRATING BIOLOGY & THE BEDSIDE,
https://www.i2b2.org/about/intro.html [https://perma.cc/QKR2-RYHF]; Griffin M.
Weber et al., The SharedHealth ResearchInformationNetwork (SHRINE): A Prototype
FederatedQuery Tool for ClinicalDataRepositories,16 J. AM. MED. INFORMATICS AsS'N
624, 625 (2009).
43 Doug Fridsma, Join Query Health in DevelopingNationalStandardsfor Population
Queries, HEALTHIT (Sept. 23, 2011), https://www.healthit.gov/buzz-blog/from-the-onc-

desk/queryhealth/ [https://perma.cc/R2DH-J4P3].
44 Patient Protection and Affordable Care Act of 2010, supra note 28, at § 1201 (current
version at 42 U.S.C. H§ 300gg-1, 300gg-2 (2010)).
45

Id.

46

1. Glenn Cohen et al., The Legal andEthical Concerns thatArisefrom Using Complex

PredictiveAnalytics in Health Care, 33 HEALTH AFF. 1139, 1143 (2014) (arguing that

obtaining informed consent in such circumstances would be unworkable).
47

Id. at 1144; Sharona Hoffman et al., E-Health Hazards: ProviderLiability and

ElectronicHealth Record Systems, 24 BERKELEY TECH. L.J. 1523, 1548, 1553 (2009)

(arguing that clinicians and physicians can be liable for use faulty predictive models or
ignoring recommendations); Halamka, supra note 18, at 1136-37 (arguing that data quality
and inconsistencies pose liability problems for users of predictive models).
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Some of these concerns are indeed novel, but many are not. In
previous work, I have traced how contemporary handwringing over
computerized medicine echoes the earliest concerns raised in the
1970s, when many potential uses were first conceived.1S In addition to
the concerns above, policymakers have long worried about regulating
computerized medicine too early, too stringently, or too clumsily, in a
way that failed to account for the unique nature of software.49 Over the
decades, observers have also worried about regulators that lack
expertise overseeing an industry (software) that has largely been
spared from federal regulation.50 Finally, a persistent concern is that
any regulation of computerized medicine would necessarily constitute
regulation of medical knowledge itself.51
There is a growing literature that wrestles with these questions in
depth. But here, I want to isolate a discrete challenge-how to
substantiate health claims made by predictive analytics. The types of
claims I have in mind are not claims to improve efficiency or resource
allocation or research findings, but claims that a predictive analytics
program will improve patient outcomes. For example, what kind of
substantiation should we require of a mobile application that claims to
distinguish ordinary moles from skin cancers based on pattern
recognition and deep learning? Or machine learning software that
claims to identify suicide risks among veterans? Or an artificial
intelligence engine that claims to offer targeted therapies to cancer
patients based on customized recommendations? What kinds of
evidence, and how much of it, should we require?
IV.

EXISTING PARADIGMS

The answers depend, to a large extent, on how we characterize
predictive analytics in health care. Three existing paradigms might
lend themselves here, though none fit perfectly. If we characterize
predictive analytics as a medical product, akin to a drug or device,
then purveyors will be required by the U.S. Food and Drug
Administration (FDA) and Federal Trade Commission (FTC) to
Cortez, Analog Agency, supranote 19, at 441, 447-51. For an early prediction that
computers would gradually replace physicians, see JERROLD S. MAXMEN, THE POST48

PHYSICIAN ERA: MEDICINE IN THE 21ST CENTURY 93 (David Mechanic ed., 1976).
49 See
50

Cortez, Analog Agency, supra note 19, at 447-51.

Id. at 449-50.

s Id. at 450-51.
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substantiate their claims with valid scientific evidence, possibly
clinical trials. If we characterize predictive analytics as a form of
medical practice, then perhaps we treat the algorithm like a physician
and require some sort of threshold license before clinical use and
subject the algorithm to a reasonable standard of care? If we
characterize predictive analytics as medical knowledge or information,
then perhaps we leave traditional regulation out of it, and rely on peer
review or some equivalent?
A. The Medical ProductParadigm
Characterizing predictive analytics as medical products would
require claims to be substantiated in the same way claims for drugs,
devices, and other medical products are substantiated. There is not, of
course, a single evidentiary standard for all product claims; the
standard varies depending on the type of product, the novelty of its
claims, and the agency asserting jurisdiction.
For example, the FTC oversees health claims in advertising and
marketing,52 and requires substantiation through "competent and
reliable scientific evidence."ss This means that the evidence, "when
considered in light of the entire body of relevant and reliable scientific
evidence, is sufficient to substantiate that the representation is true."54
Claims must have substantiation before they are made, though the
FTC does not require preapproval. But for certain health claims, such
as claims made about specific diseases, the FTC can require
randomized, double-blinded, placebo-controlled clinical trials, as it
did for POM Wonderful's claims that its juice products could help
treat or prevent heart disease, cancer, and other conditions.ss
Although the FTC does not always require randomized trials, the
agency has filed several complaints against mobile app developers
- Although the F.T.C. has responsibility for over 70 separate statutes, see FED. TRADE
COMM'N., FEDERAL TRADE COMMISSION AcT: INCORPORATING U.S. SAFE WEB Act
AMENDMENTS AS OF 2006,

https://www.ftc.gov/sites/default/files/documents/statutes/federal-trade-commissionact/ftc act-incorporatingus safe web-act.pdf [https://perma.cc/78HX-9VTE], we are
primarily concerned here with sections 5 and 12 of the FTC Act, which prohibit unfair or
deceptive trade practices and false advertising. See 15 U.S.C. §§ 45, 52.
53 POM Wonderful v. F.T.C., 777 F-3d 478, 489 (D.C. Cir. 2015), cert. denied, 136 S. Ct.

1839 (2016).
54 [d-

ss Id.
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making dubious health claims, such as an app claiming to improve
vision, an app claiming to accurately measure blood pressure, and
apps claiming to detect melanomas using smartphone imaging.5 6
Thus, predictive analytics programs claiming to diagnose, treat, or
manage specific health conditions must be able to produce competent
and reliable scientific evidence to substantiate their claims, though the
FTC has yet to articulate in many cases precisely what such evidence
might look like.
Health claims are also subject to FDA oversight if the product
qualifies as a medical "device."s7 Over the last few decades, there has
been considerable confusion over when software qualifies as a
"device" subject to FDA jurisdiction.5 8 But in the last few years, both
the FDA and Congress have tried to provide more clarity,59
56 Carrot Neurotechnology, Docket No. C-4567 (F.T.C., Feb. 22, 2016),
https://www.ftc.gov/system/files/documents/cases/16O223carrotneurodo.pdf
[https://perma.cc/728F-BTHW]; FTC v. Aura Labs, No.8:16-cV-2147-DOC (C.D. Cal. Dec.
9, 2016),

https://www.ftc.gov/system/files/documents/cases/161212_auralabs-finalorder.pdf
[https://perma.cc/7YQF-XQR4]; Health Discovery, (F.T.C., 2015),

https://www.ftc.gov/system/files/documents/cases/complaint.pdf

[https://perma.cc/6PNF-7HBS]; FTC, FTC CRACKS DowN ON MARKETERS Of "MELANOMA
DETECTION" APP (Feb. 23, 2015), https://www.ftc.gov/news-events/pressreleases/2015/o2/ftc-cracks-down-marketers-melanoma-detection-apps
[https://perma.cc/VK58-C7DN]; FTC, MOBILE HEALTH APP DEVELOPERS: FTC BEST
PRACTICES, https://www.ftc.gov/tips-advice/business-center/guidance/mobile-health-

app-developers-ftc-best-practices [https://perma.cc/CQ63-YEXN]; see generally, FTC,
HEALTH CLAIMs, https://www.ftc.gov/tips-advice/business-center/advertising-andmarketing/health-claims [https://perma.cc/AW5Y-76Z4].
57 Federal Food, Drug, and Cosmetic Act § 201(h) (2012); 21 U.S.C. § 321(h) (2012).
58 See, e.g., Cortez, Mobile Health Revolution, supra note 3; Cortez, Analog Agency, supra
note 19; Nathan Cortez, I. Glenn Cohen, & Aaron S. Kesselheim, FDA RegulationofMobile
Health Technologies, 371 N. ENG. J. MED. 372, 374 (2014).
59 Food and Drug Administration Safety and Innovation Act (FDASIA)

§ 618, Pub. L. No.
112-144, 126 Stat. 1063 (2012); U.S. Food & Drug Admin., FDASIA HEALTH IT REP. (April

2014),

https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDRH/CDRHReports/UCM391521.pdf [https://perma.cc/AZL2-NVMR]; U.S.
Food & Drug Admin., MOBILE MEDICAL APPLICATIONS: GUIDANCE FOR INDUSTRY AND FOOD
AND DRUG ADMINISTRATION STAFF (Feb. 9, 2015),

https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidanc
eDocuments/UCM263366.pdf [https://perma.cc/U95R-WM5H]. Note that the FDASIA
Health IT working group recommended against FDA regulation of data analytics, see, DW
Bates, DRAFT FDASIA COMMITrEE REP.,

http://www.healthit.gov/facas/sites/faca/ffiles/FDASLARecommendationsDrafto3o9l3_v
2.pdf [https://perma.cc/R7LD-FB2E], unless used for "strong" clinical decision support or
used in regulated medical devices. FDASIA HEALTH IT REP., supra note 59.
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culminating in late 2016, when Congress passed the 21st Century
Cures Act. 6o The Act amended the statutory definition of "device" to
exempt from FDA jurisdiction certain types of software ncluding
software used for administrative purposes, wellness and lifestyle
purposes, patient record purposes, and some clinical decision support
purposes. 6 1
The new definition includes some interesting wrinldes for
predictive analytics. First, it defines administrative software as
software intended for processing "information about patient
populations, admissions, practice and inventory management,
analysis of historical claims data to predict future utilization or costeffectiveness, determination of health benefit eligibility, population
health management, and laboratory workflow." 62 Thus, predictive
analytics used for hospital triage, resource allocation, or workflows
would not, by definition, fall within FDA jurisdiction.
Second, the new definition exempts software intended to transfer,
store, or display data from patient records, laboratory tests, or other
device inputs, unless it is "intended to interpret or analyze" these
data. 63 As such, predictive analytics that generate customized
treatment recommendations might qualify as medical "devices"
subject to FDA review.
Third, a closely related exemption carves out from the definition of
"device" clinical decision support software unless the professional
using it cannot "independently review" the basis for its
recommendations and the professional is intended to rely on the
recommendation as a primary point for diagnosing or treating a
specific patient. 64 This standard recalls the FDA's 1987 policy that
exempted from agency scrutiny decision support software, but only if
it allowed time for "competent human intervention," meaning that
"clinical judgment and experience can be used to check and interpret a
system's output" before "any impact on human health." 6 5 Like the
60 21st Century Cures Act, Pub. L. No. 114-255, § 3060; 130 Stat. 1033 (2016).
61 Id. at § 3o60(a) (codified at 21 U.S.C.

§ 3 6 oj(o)).

62

Id. at § 3o60(a) (codified at 21 U.S.C. § 3 6 oj(o)(1)).

63

Id. at

§ 3o60(a)

(codified at 21 U.S.C.

§§

360j(0)(1)(C), (D)).

64 Id. at § 3o60(a) (codified at 21 U.S.C. § 36oj(0)(1)(E)).
65 See Cortez, Mobile Health Revolution, supra note 3, at 1220 (discussing the FDA's 1987
Draft Policy Guidance for Regulation of Computer Products, 52 Fed. Reg. 36,104 (Sept. 25,
1987), and the FDA's 1989 Draft Policy for the Regulation of Computer Products (Nov. 13,
1989), available at 1989 WL 1178702).
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earlier FDA standard, the 21st Century Cures Act overlooks modern
thinking on human-computer interaction (HCI) and automation bias,
which teaches that we are dangerously predisposed to trust computergenerated advice, even when we have reason to suspect that it errs. 66
Fourth, the new definition of "device" in the Cures Act also
declines to exempt software that processes data from medical images,
in vitro diagnostics, or signal and pattern acquisition systems 67--rich
data sources that many hope will populate artificial intelligence
engines for years to come.
Finally, notwithstanding the broad exemptions, the FDA can,
through notice-and-comment in the Federal Register, assert
jurisdiction over software that would otherwise be exempt if the
agency finds that it "would be reasonably likely to have serious
adverse health consequences." 6 8 This may prove to be an important
regulatory backstop when a predictive analytics program that initially
falls outside FDA jurisdiction later evolves, increasing both its
predictive powers and perhaps its ambitions (and intended uses).
Thus, the question of whether the FDA can regulate claims made
by a predictive analytics program is an exercise of complex, somewhat
tedious statutory construction. If the program is subject to FDA
oversight, the agency will expect marketing claims to be truthful and
not misleading, which again may require substantiation via clinical
trials. Or, perhaps over time, if a predictive analytics program is
"substantially equivalent" to an older predicate on the market, the
FDA might clear the product for marketing based on a showing that it
is at least as safe and effective as the previous, legally marketed
device. 69 One important barrier to a finding of "substantial
equivalence," however, is when the newer device has a different
intended use than the predicate.70 For example, a machine learning
program designed to target one disease would not be substantially
equivalent if repurposed to target a different disease.
The FDA also expects software under its jurisdiction to satisfy
validation requirements, which help ensure that the software operates
66 Id.

at 1226-27.

67 21St

Century Cures Act, supra note 6o, at § 3o6o(a) (codified at 21 U.S.C. §

36oj(o)(1)(E)).
68 Id.

at § 3o60(a) (codified at 21 U.S.C. § 3 6 oj(o)(3))-

69 21 C.F.R.

§ 8o7.92(a)(3) (2017).

70 Id. at § 807.81(a)(3).
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according to user needs and intended uses. 71 Thus, the FDA might
expect predictive analytics programs to validate the model's
sensitivity, predictive values (positive and negative), c-statistics, and
other performance metrics.72 Scholars have called for more rigorous

validation of predictive analytics models if the risks to patients is
relatively high.73 For example, "if the model's predictions could direct
clinicians to withhold interventions recommended by current
evidence-based guidelines," the model might warrant outcomes and
analysis plans, peer review, and other robust validation methods.74 If
the risks to patients are low, perhaps less rigorous validation, such as
post-hoc outcomes comparisons, might suffice.7s
The problem with applying the FDA's product-based model to
predictive analytics is that it doesn't fit particularly well. The FDA's
medical device framework was developed in 1976 with more
traditional, tangible devices in mind. Few devices then were controlled
by, or even incorporated, software. At the time, only science fiction
writers speculated about the types of technologies used today.7 6 But by
2006, more than half of all medical devices on the U.S. market
incorporated software.77 This shift occurred with very little change in
the FDA's statutory authority or approach to regulating medical
devices.7 8 Today, then, medical devices are vastly different than in
1976, but the FDA's basic approach is not. It is thus unsurprising that
developers are frustrated with the time it takes FDA to clear both new

See U.S. FOOD & DRUG ADMIN., GENERAL PRINCIPLES OF SOFTwARE VALIDATION; FINAL
GUIDANCE FOR INDUSTRY AND FDA STAFF (2002); U.S. FOOD & DRUG ADMIN., GUIDANCE
FOR THE CONTENT OF PREMARKET SUBMISSIONS FOR SOFIWARE CONTAINED IN MEDICAL
DEVICES (2005); 21 C.F.R. § 820.3(z) (2017).
71

72

Cohen et al., supra note 46, at 1143.

73 Id.

at 1142.

74 Id.

75 Id.

Cortez, Mobile HealthRevolution, supra note 3, at 1175-76 (recounting the famous
medical Tricorder from Star Trek).
76

77 Kevin Fu, Trustworthy Medical Device Software, Institute of Medicine Workshop on the

FDA's 510(k) Process at 35 Years (2011) (prepublication draft),
https://spqr.eecs.umich.edu/papers/fu-trustworthy-medical-device-software-IOMu1.pdf
[https://perma.cc/45UL-PNHQ].
78 Cortez, Analog Agency, supra note 19, at 450-51.
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products and modifications to existing products.79 Moreover, the
FDA's validation requirements might be particularly difficult to apply
to predictive analytics models that are non-transparent, such as when
the model relies on artificial intelligence or machine learning that
evolves frequently--so-called "black box medicine."so These
complications make predictive analytics seem more like medical
practice than medical products.
B. The Medical PracticeParadigm
Is it more appropriate to characterize predictive analytics as a
form of medical practice? Consider an example. In January 2017,
Stanford researchers demonstrated that a deep learning program
could diagnose skin cancers on equal footing with dermatologists. 8 1
Using a Google-based deep convolutional neural network that was
pre-trained on 1.28 million images for 1,ooo different object
categories, the researchers then trained the algorithm on 129,450
images of skin lesions labeled by dermatologists, containing a
taxonomy of 2,032 different diseases.8 2 The researchers then tested
the deep neural network against 21 board-certified dermatologists,
using 370 high-quality images. 83 The results, published in Nature,
showed that the deep neural network matched the dermatologists,
using a sensitivity-specificity curve to calculate the proportion of
malignant and benign lesions classified correctly. 84 The researchers
were optimistic that use of the deep learning program-including its
use on mobile devices--could greatly improve early detection of skin
cancers, though they emphasized that "rigorous prospective
validation" would be required before use by clinicians or patients.8 5
79 Cortez et al., supra note 58, at 373-75.
so Cohen et al., supra note 46, at 1142-43; Price, supra note 11, at 421.
8 Andre Esteva et al., Dermatologist-LevelClassificationofSkin Cancer with Deep Neural
Networks, 542 NATURE 115, 115 (Feb. 2, 2017).
82 Id.
83

Id. at 115, 118.

84

Id. at 117-18.

85

Taylor Kubota, Deep LearningAlgorithm Does as Well asDermatologistsin Identifying

Skin Cancer, STANFORD NEWS (Jan. 25, 2017),

http://news.stanford.edu/2o17/o1/25/artificial-intelligence-used-identify-skin-cancer/
[https://perma.cc/2L7H-8MK3].
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What kind of substantiation should we require for an algorithm like
this?
Regulating such an algorithm like medical practice would have
bizarre but provocative implications. For example, there is little
equivalent for training algorithms the way we train
dermatologists-through four years of medical school, a one-year
internship in general practice, a three-year residency practicing under
experienced dermatologists, and perhaps a one-year fellowship, not to
mention passing the obligatory state medical boards and certification
by the American Academy of Dermatology. All are predicates to calling
oneself a dermatologist. Of course, the training and testing does not
stop there. The practitioner must also maintain all licenses and
certifications, which requires occasional continuing medical education
(CME) and perhaps more tests. Finally, the practitioner may haveto
obtain staff privileges at one or more hospitals and thus be subject to
hospital credentialing, peer review, and other quality control efforts.
During these years, the student-turned-dermatologist would examine
untold numbers of skin lesions, ideally developing a highly-trained
intuition that is refined over time by even more training and
experience.
The algorithm, by contrast, is trained almost by brute force. The
skin cancer algorithm above "requires no hand-crafted features: it is
trained end-to-end directly from image labels and raw pixels," fed by
well over a million pre-training and training images. 86 Yet, despite the
different training methods, both the dermatologist and the algorithm
learn "rules" for diagnosing cancers through data-albeit different
kinds of data.87
Although the algorithm matched the performance of the 21
dermatologists, neither group could classify every image accurately.
Indeed, it might be unrealistic or unfair to expect infallibility from an
algorithm and thus hold it to a higher standard than physicians,
whose fallibility and errors are well documented.88 Thus, if we
characterize predictive analytics as a form of medical practice,
perhaps we validate its performance against physician performance as
a barometer? This approach is both intuitive and symmetrical.
86 Esteva et al., supranote 81, at 115.
8

7 Ziad Obermeyer & Ezekiel J. Emanuel, Predictingthe Future - Big Data, Machine

Learning, and ClinicalMedicine, 375 NEW ENG. J. MED. 1216, 1217 (2016).
88

For the iconic study, see INSTITUTE OF MEDICINE, To ERR IS HUMAN: BUILDING A SAFER

HEALTH SYSTEM 39 (20oo), https://www.nap.edu/read/9728/chapter/1
[https://perma.cc/HP28-ED8T].
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However, the symmetry is distorted when accounting for
marketing claims. Physicians usually avoid making the more strident
claims that emerge from corporate sales and marketing departments,
deterred perhaps by professional norms, the threat of malpractice
liability, or both (although companies, in theory, are also constrained
by the threat of product liability and unfair trade practice laws). 89
Physicians cannot, and thus generally do not, guarantee results,90 in
contrast to some products. Thus, although it seems perfectly natural
to measure the performance of predictive analytics against the
performance of physicians, it seems unnatural to expect companies to
restrain their marketing claims the same way physicians do. After all,
the familiar disclaimer in advertisements that "Results may vary" is
only necessary when the advertisement implies the very opposite.
The answer, perhaps, is to subject predictive analytics to the same
legal duty of care we expect from practitioners, or hospitals, or from
medical products9'-though again, the duty will vary depending on
whether we characterize the technology as medical practice, as a
medical product, or as a medical enterprise such as a hospital.
Regardless, it may prove exceedingly difficult to determine when an
algorithm falls below the standard of care (in the case of medical
malpractice or corporate negligence claims) or is defective (in the case
of product liability claims).92 On what basis could we call a machine
learning algorithm or a deep neural network "sub-standard" or
"defective"? If it underperforms practitioners? If it underperforms
other predictive analytics programs?
In sum, characterizing predictive analytics as a form of medical
practice has intuitive appeal because it relies on a standard of
reasonable care, based on what we expect of contemporary
practitioners. But there may be no good analog in medical practice
regulation for substantiating health claims.

89

See, e.g., Nicolas P. Terry & Lindsey F. Wiley, Liabilityfor Mobile Health and Wearable

Technologies, 25 ANNALS HEALTH L. 62, 70 (2016); Nathan Cortez, The Evolving Law and
Ethics ofDigitalHealth, in DIGITAL HEALTH: SCALING HEALTHCARE TO THE WORLD

(forthcoming 2017) [hereinafter Cortez, The Evolving Law].
90 Terry & Wiley, supra note 89, at 70.

See, id.; see Cortez, The Evolving Law, supra note 89 (describing medical licensing,
medical malpractice, enterprise liability, and product liability as it applies to digital health
products).
91

92

See Terry & Wiley, supra note 89, at 70-71; See Cortez, The Evolving Law, supra note

89.
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C. The Medical InformationParadigm
Is it more appropriate to characterize predictive analytics merely
as medical information, akin to a medical journal article, a reference
text, or even an interactive web site? Policymakers have long worried
that regulating medical software would equate to regulating medical
knowledge-which of course is unregulated in any traditional sense. 93
The closest thing to quality control we have for medical textbooks,
journal articles, and reference sources is peer review and professional
editing. Some observers even worry that government regulation of
medical software might violate First Amendment rights insofar as it
restricts the dissemination of medical information as speech.94
Indeed, the government's core relationship with medical information
is to subsidize it, not regulate it.95
The clear implication of characterizing predictive analytics -as
medical information, then, is to effectively exempt it from any
oversight. This paradigm may be appropriate for predictive analytics
used for research purposes, but it would seem unfair to medical
professionals, medical products, and medical institutions that are
subject to much more stringent requirements, based on public health
and safety rationales. Eventually, the more we begin to rely on
predictive analytics to make clinical decisions, the more absurd it
seems to characterize it as mere medical information, akin to a
medical reference text.
V. CONTOURS OF A NEW PARADIGM?

If predictive analytics does not fit well into existing frameworks
governing medical products, medical professionals, or medical
information, what would a more appropriate framework look like?
There is a fair bit of skepticism of traditional regulation by traditional
regulators; conversely, there is a fair bit of optimism in private
certifiers and technology-enabled intermediation.9 6 The FDA itself, in
93 Cortez, Analog Agency, supra note 19, at 450-51.
94 Id.
95 The best examples here may be the Human Genome Project and the BRAIN Initiative,
through which the federal government has spent billions subsidizing research, in addition
to the billions spent by the NIH (National Institutes of Health) each year.

FDASIA Health IT Report, supra note 59; Price, supra note 11; U.S. Food and Drug
Admin., FDASIA Health IT Report: Proposed Strategy and Recommendations for a RiskBased Framework (Apr. 2014),
96
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fact, announced in 2017 that it was going to experiment with the use
of private certifiers for digital health products.97 Calls for Congress to
authorize more tailored regulation by the FDA9 8 were met instead
with relatively tepid clarifications in the 21st Century Cures Act that
nevertheless failed to address longstanding confusion over clinical
decision support and other big picture questions. Still, if Congress
ever were to contemplate a new framework, it should consider the
following principles:
First, there is widespread agreement that not all medical software
requires regulation, such as administrative software, software targeted
at general fitness and well-being, and other low-risk software; the
focus instead should be on software that claims to help diagnose or
treat patients and presents moderate to high risks.99 Nevertheless,
given how easy it can be to modify software and add functions,
policymakers should anticipate that otherwise benign software can
easily evolve or be merged with other programs, thus breaching
regulatory boundaries. There is also evidence that developers
frequently design around the jurisdiction of regulators like the FDA.100
Thus, although there is consensus that low-risk software warrants
https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDRH/CDRHReports/UCM391521.pdf [https://perma.cc/33MZ-V6CT]; W.
Nicholson Price II, Black Box Medicine, 28 HARv. J. L. &TECH. 419,432-34 (2015); Dov

Greenbaum, Avoiding Over-Regulation in the MedicalInternet of Things, in BIG DATA,
HEALTH LAW, AND BIoErHICS (Holly Fernandez Lynch, I. Glenn Cohen, Effy Vayena, & Urs
Gasser eds.) (forthcoming, Cambridge 2018); Marcus Comiter, DataPolicyfor Internetof

Things HealthcareDevices:Aligning Patient,Industry, and Privacy Goals in the Age of
Big Data, in BIG DATA, HEALTH LAW, AND BIoErHICS (Holly Fernandez Lynch, I. Glenn
Cohen, Effy Vayena, & Urs Gasser eds.) (forthcoming, Cambridge 2018). For a more critical
assessment of private certifiers and intermediaries, see Frank Pasquale, PrivateCertifiers
and Deputiesin American Health Care, 92 N.C. L. REV. 1661, 1673,1676 (2014).
97U.S. FOOD AND DRUG ADMIN., DIGITAL HEALTH INNOVATION ACTION PLAN (July 2017),

https://www.fda.gov/downloads/MedicalDevices/DigitalHealth/UCM568735.pdf
[https://perma.cc/F7QN-DAQ6]; Nathan G. Cortez, Nicolas P. Terry & I. Glenn Cohen,
Questions About the FDA's New Frameworkfor DigitalHealth, HEALTH AFFAIRS BLOG
(Aug. 16,2017), http://healthaffairs.org/blog/2017/o8/16/questions-about-the-fdas-new-

framework-for-digital-health/ [https://perma.cc/6CWV-Z5H8].
98 Cortez et al., supra note 58, at 375; Cortez, Analog Agency, supra note 19, at 451-53.
99 See, e.g., U.S. Food and Drug Admin., supra note 96; 21st Century Cures Act, supranote
60, at § 3060.
1oo

Nicolas P. Terry, Big Dataand RegulatoryArbitragein Health Care, in BIG DATA,

HEALTH LAW, AND BIOETHICS (Holly Fernandez Lynch, I. Glenn Cohen, Effy Vayena, & Urs

Gasser eds.) (forthcoming, Cambridge 2018); Cortez, Mobile Health Revolution, supra
note 3, at 1187-88 (discussing disclaimers).
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little attention, the fluid and malleable nature of software requires
some flexibility for regulators.101
Second, any new framework should consider the software's
intended users. There is some agreement that programs targeting
patient users should receive more scrutiny than programs targeting
more sophisticated users, such as health practitioners and
institutions.102 Thus, we might logically expect more scientific

substantiation for skin cancer-detecting software when it is targeted at
smartphone users than we would for software targeted at
dermatologists.1o3 Still, history tells us that even sophisticated users
can benefit from quality screening.104 For example, practitioners are
often bewildered by the sheer number of health apps available.o5
Moreover, even world-class institutions can struggle to incorporate
predictive analytics. A recent example is MD Anderson's failed
partnership with IBM Watson, which was the subject of a scathing
audit by the University of Texas showing that MD Anderson had spent
over $62 million on the project, with little to show for it.106 Any new
1 Indeed, the backstop provided by the 21st Century Cures Act seems to provide FDA the
ability to assert jurisdiction over high-risk software that it otherwise might not regulate, so
long as the agency uses notice-and-comment procedures. See 21st Century Cures Act,
supra note 60.
102

See, U.S. FOOD AND DRUG ADMIN., MOBILE MEDICAL APPLICATIONS: GUIDANCE FOR

INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF (Feb. 9, 2015),

https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidanc

eDocuments/UCM263366.pdf [https://perma.cc/7R6S-4D8C].
103 For examples of the former, see, FTC, FTC CRACKS DOWN ON MARKETERS OF
"MELANOMA DETECION"APPS (2015),

https://www.ftc.gov/system/files/documents/cases/complaint.pdf
[https://perma.cc/KW5A-PZZC].
104

For an interesting parallel, consider that one of the major rationales for not regulating

mortgage-backed securities, credit default swaps, and other sophisticated collateralized
debt instruments was that the transactions involved highly sophisticated parties that would
fully understand the risks and benefits. That proved to be a dangerous assumption leading
up to the 2008 financial crisis. See FIN. CRISIS INQUIRY COMM'N, FINANCIAL CRISIS INQUIRY
REPORT xxiv-xxv, 47 (Jan. 2011); Nathan Cortez, Regulating DisruptiveInnovation, 29
BERKELEY TECH. L.J. 173, 183-84 (2014).
105

Cortez et al., supra note 58.

1o6 See Kubota, supranote 85. See UNIV. OF TEX. Sys. AUDIT OFFICE, SPECIAL REVIEW OF
THE PROCUREMENT PROCEDURES RELATED TO THE M.D. ANDERSON CANCER CENTER
ONCOLOGY EXPERT ADVISOR PROJECT (2016-17), at 2,

https://www.utsystem.edu/sites/default/files/documents/UT%20System%2oAdministrati
on%20Special%2oReview%200P%62oProcurement%2oProcedures%2oRelated%2oto%2oU
TMDACC%200ncology%2oExpert%2oAdvisor%2oProject/ut-system-administration-
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paradigm should carefully consider whether and how to calibrate the
appropriate level of substantiation for different users.
Third, any new framework should also consider how effective a
predictive analytics program must be before clinical or patient use. As
noted above, physician performance might be a sensible barometer.
For example, an important milestone occurred in January 2017, when
the FDA cleared the first product that relies on machine learning. The
Arterys Cardio DL uses a self-teaching neural network to measure
blood flow to the heart and thus aid cardiologists in diagnosing heart
problems.107 Arterys produced results on par with trained
cardiologists, but took only 15 seconds to accomplish what might take
a cardiologist well over 30 minutes.os Likewise, as discussed above,
the deep neural network developed at Stanford to diagnose skin
cancers produced results on par with dermatologists.1o9 It makes little
sense to prevent the use of such programs by practitioners for clinical
decision support. The tougher question is whether these results justify
use by patients and lay users. Moreover, even use by practitioners
must account for the risk of automation bias and other realities of
human-computer

interaction.nlo

Finally,

any new paradigm for

predictive analytics must also contemplate what barometers might be
appropriate for software functions that have no comparable physician
counterparts and thus lack a baseline for validation.
A variety of different frameworks might accommodate these
principles. For example, an FDA-led system for granting conditional
approvals to predictive analytics programs and then requiring robust
post-marketing studies and pre-set reevaluation timelines might
generate reliable clinical evidence without inordinately delaying

special-review-procurement-procedures-related-utmdacc-oncology-expert-advis.pdf
[https://perma.cc/KVH6-JNC7].
107 Letter from Robert Ochs, Dir., Div. of Radiological Health, U.S. Food & Drug Admin., to
Ms. Golnaz Moeini, Dir. of Quality and Regulatory, Arterys Inc, 19, (Jan. 5, 2017),

https://www.accessdata.fda.gov/cdrh-docs/pdf6/K63253.pdf [https://perma.cc/6BPKT6E6].
1os Id.; Bernard Marr, FirstFDA Approvalfor Clinical Cloud-BasedDeep Learning in
Healthcare,FORBES (Jan. 20, 2017),
https://www.forbes.com/sites/bernardmarr/2017/01/20/first-fda-approval-for-clinicalcloud-based-deep-learning-in-healthcare/#76a2889d61c [https://perma.cc/7MDQ3TWM].
lo9 See Esteva et al., supra note 81, at 117.
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market entry.",' The agency might even rely on validation by third
parties with more expertise in predictive analytics and other complex
forms of software. Again, in June 2017, the agency announced a new
"Digital Health Program" that would use non-governmental
"certifiers" to screen digital health firms (rather than products), as
well as shift the FDA's expectations for data on safety and efficacy
from the pre-market to post-market phase.112 Forthcoming, then, are a
slew of guidances from the agency explaining how these new ideas will
be implemented.113
In the meantime, predictive analytics in health care will continue
to develop as an important new tool for diagnosing and treating
patients. But it will not reach its full potential without reliable ways to
substantiate their claimed functions. Currently, without clear
regulatory
oversight,
different
types of non-government
intermediaries are stepping in to evaluate these technologies, such as
venture capital firms with experience in the health care sector,
hospital systems, app review websites, and health insurers.114
Although each can screen and evaluate a limited number of these
technologies, often relying on published literature for substantiation,
they are at best short-term solutions for an industry that promises to
expand dramatically in the coming years.
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